Европска Унија - Енглески - EMA (European Medicines Agency)

alfasigma s.p.a. - piperaquine tetraphosphate, artenimol - malaria - antiprotozoals - eurartesim is indicated for the treatment of uncomplicated plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more.consideration should be given to official guidance on the appropriate use of antimalarial agents.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

logixx pharma solutions ltd - artenimol; piperaquine phosphate - tablet - 40mg ; 320mg

Кенија - Енглески - Pharmacy and Poisons Board

sigma tau industrie farmaceutiche riunite spa viale shakespeare 47 00144 rome - italy - piperaquine tetraphosphate + dihydroartemisinin - film-coated tablet - 320 mg pqp/40mg dha - antimalarial antiprotozoals: combinations of

Кенија - Енглески - Pharmacy and Poisons Board

sigma tau industrie farmaceutiche riunite spa viale shakespeare 47 00144 rome - italy - piperaquine tetraphosphate + dihydroartemisinin - film-coated tablet - 160 mg pqp/20mg dha - antimalarial antiprotozoals: combinations of

Намибија - Енглески - Namibia Medicines Regulatory Council

sigma-tau industrie farmaceutiche riunite s.p.a - piperaquine tetraphosphate, artenimol - tablet - each film coated tablet contains piperaquine tetraphosphate (as tetrahydrate) 320,0 mg,, artenimol 40,0 mg

Намибија - Енглески - Namibia Medicines Regulatory Council

sigma-tau industrie farmaceutiche riunite s.p.a - piperaquine tetraphosphate, artenimol - tablet - each film coated tablet contains piperaquine tetraphosphate (as tetrahydrate) 160,0 mg,, artenimol 20,0 mg

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 12.5 ug in 1 h - duragesic is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see warnings and precautions (5.1)] , reserve duragesic for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide suffi

Канада - Енглески - Health Canada

janssen inc - fentanyl - patch - 25mcg - fentanyl 25mcg - opiate agonists

Канада - Енглески - Health Canada

janssen inc - fentanyl - patch - 50mcg - fentanyl 50mcg - opiate agonists